BARDA Director Rick Bright removed; whistleblower complaint settled

Dr. Rick Bright filed an Office of Special Counsel complaint after his April 2020 removal as BARDA director, alleging retaliation for objecting to hydroxychloroquine promotion and raising early pandemic-preparedness alarms; OSC found 'reasonable grounds' within days. HHS maintained he was reassigned to NIH for performance reasons. OSC announced a settlement on August 9, 2021, with back pay and a position of his choosing — cited both as vindication of an early-warning whistleblower and, by administration defenders, as the resolution of a management dispute.